|
Jun 30
|
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
|
|
Jun 28
|
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
|
|
Jun 27
|
Kymera’s partnerships with Sanofi and Gilead drive value
|
|
Jun 27
|
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
|
|
Jun 26
|
Kymera weakness a buying opportunity, says Stifel
|
|
Jun 26
|
Morning Movers: General Mills dips following fourth quarter report
|
|
Jun 26
|
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
|
|
Jun 25
|
Kymera Therapeutics Announces Proposed Public Offering
|
|
Jun 25
|
Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal
|
|
Jun 25
|
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi
|
|
Jun 25
|
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
|
|
Jun 25
|
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
|
|
May 29
|
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
|
|
May 19
|
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
|
|
Apr 9
|
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
|
|
Feb 20
|
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27
|
|
Feb 19
|
NAYA Biosciences Announces Nomination of New Board Members
|
|
Jul 25
|
We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn
|
|
Jun 14
|
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
|
|
May 14
|
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
|